Evaluation of the Effects of Different Prostate Surgeries on Urinary and Sexual Function

May 8, 2015 updated by: Ahmed Elshal, Mansoura University

Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study.

The impact of of different surgical treatment modalities of benign prostatic hyperplasia in men on their sexual function is not well studied.

The investigators will investigate prospectively the effect of conventional monopolar transurethral resection of the prostate (TURP), bipolar TURP and Holmium laser enucleation on urinary and sexual functions.

Study Overview

Detailed Description

Benign prostatic hyperplasia (BPH), one of the most common diseases of aging men, can be associated with bothersome lower urinary tract symptoms (LUTS) that affect quality of life. The prevalence of histopathologic BPH is age dependent, with initial development usually after 40 years of age. Similar to that of histologic evidence, the prevalence of bothersome symptoms also increases with age. Approximately half of all men who have a histologic diagnosis have moderate to severe LUTS.

The other common disorder associated with BPH is sexual dysfunction based purely on age. Sexual dysfunction encompasses not only erectile dysfunction (ED), but also ejaculation abnormalities, difficulty in reaching orgasm, decreased libido and overall dissatisfaction. Many studies suggest that the presence of LUTS is a risk factor for sexual dysfunction. Increasing life expectancy has been associated with improvements in the health and quality of life of the elderly, and many studies examined the sexuality of these groups of subjects and reported that their interest in sex persist.

By reviewing the literature, the effect of different modalities for treating BPH, including medical, open surgical, endourological procedures, on urinary function has been extensively discussed and to a less extent on sexual function. A significant problem which arises when discussing the sexual function with patients and partners, and when reviewing the literature, is to know which aspect of male sexual function is being referred to.

Transurethral resection of the prostate (TURP) is still considered the gold standard in treating BPH. However, most authors accept that there will be some impairment of sexual function secondary to this procedure. The exact magnitude of this problem has been difficult to assess by reviewing the published literature. Most of the large series reported ED rates of 10 to 15%. (11&12) The etiology of ED secondary to TURP is poorly understood. Most likely it is secondary to electrical trauma to the cavernous nerves close to the prostate apex at 5 and 7 o'clock positions. Furthermore, thrombosis of the cavernosal arteries may result from mechanical trauma or from thermal damage.

Post TURP ejaculatory dysfunction was reported and documented to be in the form of retrograde ejaculation in between 25-99 %. The mechanism for that was destruction of the bladder neck mechanism which is responsible for sympathetic mediated occlusion of the bladder neck during ejaculation ending in forward expulsion of the ejaculate.

Since introduction of TURP as an effective tool for treatment of BPH, many endo-urologic techniques were tried to overcome the limitations and drawbacks of this gold standard procedure mainly caused by perioperative bleeding requiring transfusion or re-intervention, irrigation fluid absorption (TUR syndrome) and need for hospital stay.

Currently holmium laser enucleation of the prostate (HoLEP) seems to be an attractive alternative to standard TURP. The efficacy and safety of HoLEP have been demonstrated even in cases of large prostates that otherwise would usually require open prostatectomy. In several comparative randomized studies, HoLEP was found to be superior to TURP in term of catheter time, hospital stay, weight of removed tissue, blood loss but with longer operative time.

However, its impact on male sexual function has not been well established. The successful outcome of relief of LUTs is postulated to favor improving the overall sexual function. However, other factors including laser heating effect, is hypothesized to contribute to postoperative erectile dysfunction.

The safety of bipolar TURP is enhanced by the use of normal saline eliminating the incidence of the metabolite toxicities and dilutional hyponatremia and the physics of electrical current return theoretically reduce the thermal tissue damage at the site of surgery or at a distant site by faulty patient grounding ( patient return electrode pad ). Urologists have observed better intra-operative visibility during bipolar resection, which may also enhance resident education. The deep coagulation effect of bipolar resection is thought to contribute in the postoperative sexual dysfunction. However, sexual function after bipolar TURP is still not well established in the literature.

To the best of the investigators' knowledge there is no any prospective study in the literature comparing these three widely available procedures monopolar TURP, bipolar TURP and HoLEP in term of their urinary, erectile and ejaculatory outcome.

Study Type

Interventional

Enrollment (Actual)

262

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Aldakahlia
      • Mansoura, Aldakahlia, Egypt, 35516
        • Urology and nephrology center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  1. Lower urinary symptoms (LUTS) secondary to bladder outlet obstruction from BPH.
  2. Failed medical treatment of BPH.
  3. International prostate symptom score (IPSS) >9.
  4. Peak urinary flow rate (Qmax) <10 ml/sec.
  5. Patients in retention secondary to BPH.
  6. Total prostate size not less than 30 gm by TRUS (transrectal ultrasound)

    -

Exclusion Criteria:

  1. Patient who have a neurological disorder as neurogenic bladder, cerebrovascular stroke or Parkinson disease.
  2. Non BPH causes of LUTS as cystitis.
  3. Infravesical causes of LUTS other than BPH as urethral stricture.
  4. Presence of active bladder cancer (within the last 2 years).
  5. Known cancer prostate patients on the basis of digital rectal examination, prostate specific antigen level, and TRUS imaging followed by prostate biopsies if necessary.

    -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Placebo
patients who are undergoing diagnostic cystoscopy
Cysto-urethroscopy
Active Comparator: HOLEP
Holmium laser enucleation of the prostate
Laser assisted enucleation of the prostatic adenoma
Other Names:
  • HOLEP
Active Comparator: monopolar TURP
Monopolar transurethral resection of the prostate
using the monopolar electrocautery to resect the prostate adenoma
Other Names:
  • TURP
Active Comparator: Bipolar TURP
Bipolar transurethral resection of the prostate
using the bipolar electrocautery to resect the prostate adenoma
Other Names:
  • TURiS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in sexual function
Time Frame: 12 months postoperative
Sexual function questionnaire (change in the score from baseline)
12 months postoperative

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in urinary function
Time Frame: six months postoperative
symptoms score (IPSS), urine flow rate (Q-max) and postvoid residual urine (PVR)
six months postoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2013

Primary Completion (Actual)

April 1, 2014

Study Completion (Actual)

April 1, 2015

Study Registration Dates

First Submitted

March 10, 2013

First Submitted That Met QC Criteria

March 11, 2013

First Posted (Estimate)

March 13, 2013

Study Record Updates

Last Update Posted (Estimate)

May 12, 2015

Last Update Submitted That Met QC Criteria

May 8, 2015

Last Verified

May 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • Mans-01-2013

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sexual Functions and Problems in the Adult

Clinical Trials on Diagnostic cystoscopy

3
Subscribe